ArticlePLoS genetics2023

ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC).

Lorenzo Ferrando et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.